Perspectum Lands Top Spot in Alantra Pharma Fast 50 Rankings
- March 01, 2021
Diagnostic imaging company helps providers better assess patient conditions, pursue targeted treatments and achieve greater patient outcomes.
OXFORD, UK, March 1, 2021. Alantra today announces it has awarded Perspectum the top spot in its 2021 Pharma Fast 50 technology category rankings and third place in the overall rankings. Each year, Alantra releases its Pharma Fast 50, ranking the UK’s fastest-growing, privately owned pharma and pharma service companies. This is the first time Perspectum has been named on the financial services firm’s annual list.
A global company headquartered in Oxford, with offices in Dallas, San Francisco and Singapore, Perspectum’s technologies provide metrics that correlate with patient outcomes and experience by using data from MRI scans to build detailed maps of organs to help physicians make accurate and cost-effective diagnoses — without invasive procedures like biopsies. The company’s software-as-a-service (SaaS) model offers practitioners an affordable entry point to its technology.
Response to the company’s imaging technologies has been strong — Perspectum revenues have increased at an annualised rate of 78 percent over the past two years. Perspectum is expanding into new therapeutic areas around the world, including a focus on long-COVID, as its CoverScanMD is the world’s first imaging service approved by UK’s MHRA for long-COVID diagnoses. The company is also expanding into precision oncology with its recent debut of Hepatica, a decision support tool for surgeons and clinicians evaluating patients pre-operatively that are being considered for liver resections.
“Perspectum is so honoured to be included on this illustrious list alongside so many of our colleagues in the UK pharmaceutical industry— we are very proud of what we’re working to accomplish. Our diagnostic technology not only allows patients to avoid invasive procedures, it offers better quality and lower-cost diagnoses,” says Dr. Rajarshi Banerjee, founder and CEO, Perspectum. “The results from our MRI screenings empower providers and patients to pursue more targeted treatments and achieve greater outcomes.”
“The Alantra Pharma Fast 50 illustrates the strength and depth of the UK’s thriving pharmaceutical sector, with smaller privately-owned businesses often leading their markets and competing globally to achieve better outcomes for patients,” said Tom Cowap, director, pharma services, Alantra. “These businesses have been able to combine their specialist expertise and experience with an agile entrepreneurial culture to drive growth.”
To view the full 2021 Pharma Fast 50 report, click HERE.
Perspectum delivers cutting-edge digital technologies that help clinicians provide better care for patients with liver disease, diabetes and cancer. With a strong focus on precision medicine using advanced imaging and genetics, it empowers patients and clinicians through quantitative assessments of health enabling early detection, diagnosis, and targeted treatment without invasive procedures. Its CoverScanMD is a multi-organ imaging suite to support healthcare professionals in the screening and management of COVID-19 by simultaneously characterizing the heart, kidneys, spleen, liver, lungs and pancreas. With a diverse team of physicians, biomedical scientists, engineers and technologists, Perspectum offers a way to manage complex health problems at scale. For more information, visit perspectum.com.
+44 753 1785361